Skip to main content
. 2022 May 6;14(5):1002. doi: 10.3390/pharmaceutics14051002

Figure 14.

Figure 14

Anticancer mechanism of U87-Selu exo compared with selumetinib. (a) Western blot of each group treated for 0.5, 1, or 3 h. (b) pERK expression levels of control, U87-Selu exo, and Selu only. (c) pMEK expression levels of control, U87-Selu exo, and selumetinib only. * p < 0.05, *** p < 0.001 vs. non-treated control for each time point, n = 3.